Tenet Healthcare (THC) Q4 Earnings: What To Expect

Hospital operator Tenet Healthcare will be reporting results this Wednesday before market hours. Here’s what you need to know. Tenet Healthcare beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $5.29 billion, up 3.3% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and a decent beat of analysts’ full-year EPS guidance estimates. Is Tenet Healthcare a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.This quarter, analysts are expecting Tenet Healthcare’s revenue to grow 7.8% year on year to $5.47 billion, a reversal from the 5.7% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.05 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tenet Healthcare has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Tenet Healthcare’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. HCA Healthcare delivered year-on-year revenue growth of 6.7%, missing analysts’ expectations by 1%, and DaVita reported revenues up 9.9%, topping estimates by 3.2%. HCA Healthcare traded up 4% following the results while DaVita was also up 21.2%. Read our full analysis of HCA Healthcare’s results here and DaVita’s results here.The euphoria surrounding Trump’s November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.6% on average over the last month. Tenet Healthcare is down 2.6% during the same time and is heading into earnings with an average analyst price target of $237 (compared to the current share price of $197.37).